EMCIP
RPRX icon

Ewing Morris & Co Investment Partners’s Royalty Pharma RPRX Stock Holding History

Ewing Morris & Co Investment Partners’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-28,522
Closed -$1.03M – 114
2025
Q2 		$1.03M Buy
+28,522
New +$945K 0.46% 53

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ewing Morris & Co Investment Partners's RPRX Position: Q3 2025 in Review

Ewing Morris & Co Investment Partners sold out of Royalty Pharma (RPRX) in Q3 2025, closing a stake of 28,522 shares — an estimated $1.03M sold.

Ewing Morris & Co Investment Partners first reported a position in RPRX in Q2 2025 and held it in 1 quarter. The position peaked at $1.03M in Q2 2025. 487 funds tracked by Wall St. Rank hold RPRX as of Q3 2025.

  • Ewing Morris & Co Investment Partners reported no remaining Royalty Pharma position as of Q3 2025 after selling out during the quarter.
  • Ewing Morris & Co Investment Partners sold 28,522 Royalty Pharma shares in Q3 2025, an estimated $1.03M.
  • Ewing Morris & Co Investment Partners first reported a position in Royalty Pharma in Q2 2025 and held it in 1 quarter.
  • Ewing Morris & Co Investment Partners's Royalty Pharma position peaked at $1.03M in Q2 2025.
  • 487 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2025.

Based on Ewing Morris & Co Investment Partners's 13F filing for Q3 2025, filed 14 Nov 2025.